This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): alpha-galactosidase A, agalsidase beta
Description: Fabrazyme is a recombinant human alpha-galactosidase A enzyme, which is deficient in patients with an inherited disorder called Fabry Disease. Fabry disease is a progressive, destructive, life-threatening, X-linked disorder of glycosphingolipid metabolism. Fabrazyme is intended to provide an exogenous source of the deficient enzyme in patients with this disease.
Deal Structure: In December 2009, Genzyme and Hospira entered into an agreement for Hospira to perform fill and finish manufacturing services for Genzyme's products Cerezyme, Fabrazyme, Myozyme and Thyrogen.
In June 2010, Genzyme and Hospira entered into an agreement for Hospira to perform fill and finish manufacturing services for Genzyme's products, including Cerezyme, Fabrazyme, Myozyme, Lumizyme, Thyrogen, Thymoglobulin, Campath and certain of Genzyme's product candidates in development. This agreement replaces prior agreements between Genzyme and Hospira regarding fill and finish services, including the Technology Transfer and Supply Agreement dated as of December 31, 2009.
In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange...See full deal structure in Biomedtracker
Pink Sheet End Of The 'March-In' Pricing Petitions?
Additional information available to subscribers only: